Growth Hormone Therapy Denied? How to Appeal

Growth hormone therapy is one of the most commonly denied specialty treatments — and also one of the most commonly overturned on appeal. Somatropin products including Genotropin, Humatrope, Norditropin, Nutropin, and Saizen are high-cost injectable medications that insurers scrutinize intensively. Whether you are seeking treatment for a child with documented growth failure or an adult with confirmed growth hormone deficiency (GHD), the key to a successful appeal is understanding exactly which diagnostic criteria the insurer is applying and building your case against those specific standards with complete clinical documentation.

Why Insurers Deny Growth Hormone Therapy Claims

Growth hormone therapy denials follow predictable patterns, and knowing which applies to your situation is essential before drafting your appeal:

• Insufficient diagnostic testing: Health plans typically require specific stimulation tests to confirm GHD in adults. Common required tests include the insulin tolerance test (ITT), glucagon stimulation test, or macimorelin stimulation test. If the testing does not match the insurer's approved protocol, or if results are not clearly documented with peak GH levels, the claim will be denied. Many plans no longer accept the arginine-GHRH test following FDA withdrawal of the Geref kit
• Failure to meet pediatric criteria: Pediatric GH therapy (ICD-10: E23.0 for hypopituitarism/GHD, E34.3 for short stature due to endocrine disorder) is generally covered when a child falls below the third percentile for height, demonstrates a growth velocity significantly below normal for chronological and bone age, and has confirmed GHD on stimulation testing with a peak GH less than 10 ng/mL on two separate tests under most plan criteria
• Off-label indication: Growth hormone is FDA-approved for a defined set of indications including pediatric GHD, adult GHD, Prader-Willi syndrome (Q87.1), Turner syndrome (Q96.x), Noonan syndrome, chronic renal insufficiency, small for gestational age without catch-up growth, and idiopathic short stature in certain cases. Use outside these indications is likely to be denied as experimental
• Step therapy requirements: Some plans require documented trial of lower-cost or biosimilar GH products before approving the prescribed brand
• Maintenance claim denials: Continuation claims may be denied if follow-up documentation does not demonstrate adequate response or compliance with treatment

How to Appeal a Growth Hormone Therapy Denial

Step 1: Request the Complete Denial and Clinical Policy Bulletin

Ask your insurer for the full denial letter, the specific coverage criteria applied, and the Clinical Policy Bulletin (CPB) or coverage determination document relevant to growth hormone therapy. Most major insurers including Cigna, Aetna, UnitedHealthcare, and BCBS plans publish CPBs defining their diagnostic thresholds. Compare the denial reason against your actual clinical documentation point by point before drafting your appeal.

Step 2: Confirm Correct ICD-10 and Diagnosis Coding

Coding errors are a significant source of wrongful denials. Verify your claim uses the correct codes: E23.0 for hypopituitarism (includes GHD), E34.3 for short stature due to endocrine disorder, Q96.x for Turner syndrome, Q87.1 for congenital malformation syndromes associated with short stature including Noonan and Russell-Silver syndromes, and Z00.2 for encounter for examination for growth and developmental state. For adult GHD, the Endocrine Society Clinical Practice Guideline (2011, updated 2019) defines GHD as a peak GH below 3 ng/mL on ITT or below 2.5 ng/mL on glucagon stimulation test in the appropriate clinical context.

Step 3: Compile Diagnostic Testing Documentation

Your appeal package must include all stimulation test results with peak GH levels clearly stated, IGF-1 and IGFBP-3 baseline and follow-up values, bone age X-ray report and growth velocity charts for pediatric cases, pituitary MRI if pituitary pathology is suspected or documented, records of other pituitary hormone deficiencies (TSH, ACTH, FSH/LH), and documentation of the clinical context such as history of pituitary surgery, cranial radiation, traumatic brain injury, or congenital anomaly. Adults with three or more other pituitary hormone deficiencies may not require stimulation testing under the Endocrine Society guideline — cite this explicitly if it applies.

Step 4: Obtain a Detailed Letter from Your Endocrinologist

Your endocrinologist's letter must address the specific diagnosis and how it meets the insurer's stated criteria, the testing performed and results with reference to Endocrine Society or Pediatric Endocrine Society diagnostic thresholds, the prescribed medication and dose with clinical justification, the expected clinical benefit of treatment referencing published outcomes data, and explicit citation of the Endocrine Society Clinical Practice Guidelines as the evidence base.

Step 5: Address Step Therapy Requirements

If the denial is based on step therapy, document which products have been tried, the duration of each trial, clinical response or lack thereof, and why the required step-therapy product is contraindicated or clinically inappropriate for this patient. Request a formal step therapy exception if your physician has clinical grounds for the specific prescribed product.

Step 6: File the Written Internal Appeal

Submit your appeal within the deadline in your denial letter — typically 30 to 180 days. Invoke your rights under ACA § 2719 (42 U.S.C. § 300gg-19) for fully insured plans, or ERISA § 1133 (29 U.S.C. § 1133) for employer-sponsored plans. Request specifically that a board-certified endocrinologist review the decision rather than a generalist medical reviewer.

What to Include in Your Appeal

• Full denial letter, EOB, and the insurer's Clinical Policy Bulletin for growth hormone therapy
• Stimulation test results with peak GH levels, IGF-1 and IGFBP-3 lab values, and pituitary MRI report
• Bone age X-ray report and growth velocity charts with height percentile documentation (for pediatric cases)
• Endocrinologist letter of medical necessity citing Endocrine Society or Pediatric Endocrine Society clinical practice guidelines and the patient's specific diagnostic profile
• Prior treatment records including biosimilar or alternative product trial history for step therapy denials

Fight Back With ClaimBack

Growth hormone therapy denials frequently turn on specific diagnostic thresholds and documentation completeness rather than the clinical merits of your physician's judgment. When the testing documentation is complete and the Endocrine Society guidelines are explicitly applied, these denials are reversed at a meaningful rate. ClaimBack generates a professional appeal letter in 3 minutes that targets your exact denial reason.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal